Recurrent Primary Peritoneal Serous Adenocarcinoma

Explore clinical trials studying Recurrent Primary Peritoneal Serous Adenocarcinoma. Study availability and eligibility vary by location and protocol.

2 public trials 1 recruiting study

Refine in advanced search Browse all conditions

Recurrent Primary Peritoneal Serous Adenocarcinoma trial results

Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

NCT05231122

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +29 more
Locations: Roswell Park Cancer Institute Buffalo, New York, United States

M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

NCT02101788

Conditions: Adenocarcinoma, Borderline Ovarian Serous Tumor, Carcinoma, +11 more
Locations: Tennessee Valley Gynecologic Oncology Huntsville, Alabama, United States

Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States

Anchorage Radiation Therapy Center Anchorage, Alaska, United States

Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States

View all 501 locations

View Trial Details

Recurrent Primary Peritoneal Serous Adenocarcinoma

Recurrent Primary Peritoneal Serous Adenocarcinoma trial results

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Related conditions